Information Provided By:
Fly News Breaks for August 22, 2019
Aug 22, 2019 | 15:16 EDT
JMP Securities analyst Donald Ellis reiterated an Outperform rating on Clearside Biomedical, but it lowering his price target on shares to $3 from $4 after the FDA requested additional stability data for Xipere, which will delay a final FDA approval and require an NDA re-submission in Q1 of 2020. Ellis added that he now sees Xipere approval in Q3 of 2020.
News For CLSD From the Last 2 Days
There are no results for your query CLSD